| CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by … M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ... The lancet oncology 7 (5), 379-391, 2006 | 2562 | 2006 |
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ... The Lancet 376 (9747), 1164-1174, 2010 | 2420 | 2010 |
| Follicular lymphoma international prognostic index P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ... Blood 104 (5), 1258-1265, 2004 | 2179 | 2004 |
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ... New England Journal of Medicine 370 (11), 1008-1018, 2014 | 1250 | 2014 |
| Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ... Journal of Clinical Oncology 35 (19), 2125-2132, 2017 | 1046 | 2017 |
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016 | 1013 | 2016 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 884 | 2022 |
| CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the … M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ... The lancet oncology 12 (11), 1013-1022, 2011 | 868 | 2011 |
| Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project W Au, DD Weisenburger, T Intragumtornchai, S Nakamura, WS Kim, I Sng, ... Blood, The Journal of the American Society of Hematology 113 (17), 3931-3937, 2009 | 840 | 2009 |
| ALK+ Lymphoma: Clinico-Pathological Findings and Outcome B Falini, S Pileri, PL Zinzani, A Carbone, V Zagonel, C Wolf-Peeters, ... Blood, The Journal of the American Society of Hematology 93 (8), 2697-2706, 1999 | 802 | 1999 |
| Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ... New England Journal of Medicine 378 (4), 331-344, 2018 | 782 | 2018 |
| Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients SA Pileri, S Ascani, MC Cox, C Campidelli, F Bacci, M Piccioli, ... Leukemia 21 (2), 340-350, 2007 | 779 | 2007 |
| Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm … P Armand, A Engert, A Younes, M Fanale, A Santoro, PL Zinzani, ... Journal of Clinical Oncology 36 (14), 1428-1439, 2018 | 731 | 2018 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 730 | 2019 |
| Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure P Armand, MA Shipp, V Ribrag, JM Michot, PL Zinzani, J Kuruvilla, ... Journal of Clinical Oncology 34 (31), 3733-3739, 2016 | 717 | 2016 |
| Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, ... Journal of Clinical Oncology 29 (9), 1182-1189, 2011 | 717 | 2011 |
| Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue E Zucca, A Conconi, E Pedrinis, S Cortelazzo, T Motta, ... Blood, The Journal of the American Society of Hematology 101 (7), 2489-2495, 2003 | 644 | 2003 |
| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 578 | 2018 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 573 | 2017 |
| Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ... Journal of Clinical Oncology 37 (15), 1285-1295, 2019 | 566 | 2019 |
